Evidence map›Paper›PMID 16520943›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2006

CC chemokine receptor (CCR)-2 prevents arthritis development following infection by Mycobacterium avium.

Marlon P Quinones, Fabio Jimenez, Hernan Martinez, Carlos A Estrada, Opal Willmon, Molly Dudley, William A Kuziel, Peter C Melby, Robert L Reddick, Sunil K Ahuja and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Chemokines and chemokine receptors in arthritis.Frontiers in bioscience (Scholar edition) · 2010
    Review
  4. Infections and autoimmunity: a panorama.Clinical reviews in allergy & immunology · 2008
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Marlon P QuinonesSouth Texas Veterans Health Care System, Audie L. Murphy Division, San Antonio, Veterans Administration Center for Research on AIDS and HIV-1 Infection, San Antonio, TX, USA.
Fabio Jimenez
Hernan Martinez
Carlos A Estrada
Opal Willmon
Molly Dudley
William A Kuziel
Peter C Melby
Robert L Reddick
Sunil K Ahuja
Seema S Ahuja
South Texas Veterans Health Care System · USMurphy Oil Corporation (United States) · USThe University of Texas Health Science Center at San Antonio · USPDL BioPharma (United States) · US

Funding

Chemokine System in DC and Lymphocyte FunctionR01AI048644 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI AHUJA, SEEMA SINGH · 2001 to 2005
$1.7M
NIAID NIH HHS AI48644
6 · The paper itself

Abstract

The host factors that influence autoimmune arthritides such as rheumatoid arthritis have not been fully elucidated. We previously found that genetic inactivation of CC chemokine receptor 2 (CCR2) in the arthritis-prone DBA/1j mouse strain significantly increases the susceptibility of this strain to autoimmune arthritis induced by immunization with collagen type II (CII) and complete Freund's adjuvant (CFA). Here, we show that following intradermal infection with Mycobacterium avium, a similar arthritis phenotype was detected in Ccr2-null mice in the DBA/1j, but not in the BALB/c background. The failure to develop arthritis in Ccr2-null BALB/c mice occurred in the face of high bacterial burdens and low interferon gamma (IFNgamma) production. By contrast, Ccr2-null DBA/1j mice had low bacterial burdens, produced normal amounts of IFNgamma, and had high titers of autoantibodies against CII. Thus, the Ccr2-null state in an arthritic-prone genetic background leads to increased arthritis susceptibility following infectious (M. avium) and noninfectious (CII/CFA) challenges. Because CCR2 serves as a negative regulator of murine arthritis, caution might need to be exercised while testing CCR2 blockers in human arthritis or other diseases. These findings also indicate that Ccr2-null DBA/1j mice might serve as a valuable model system to uncover the immunological determinants of arthritis and to test novel antiarthritic agents.

Indexed as

Mycobacterium aviumAnimalsArthritis, ExperimentalCollagen Type IIInterferon-gammaMiceMice, Inbred BALB CMice, Inbred DBAMice, KnockoutReceptors, CCR2Receptors, ChemokineTuberculosis, CutaneousCCR2 protein, humanCcr2 protein, mouseCollagen Type IIInterferon-gammaReceptors, CCR2Receptors, Chemokine

Identifiers

PMID16520943
OpenAlexW2159455384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.